Objective Capital


	back to homepage Objective Archives 2012: Jan \| 2011: Dec \| Nov \| Oct \| Sep \| Aug \| Jul \| ... Sofame Technologies (SDW.V) - more detail on funding plans Objective Comment, Sep 11, 2009 Read More \| Previous Reports Scancell Holdings (SCLP.PLUS) - differentiated technology and a focused plan offer ingredients for success Objective Report, Sep 08, 2009 Scancell is developing a product platform that uniquely stimulates the immune system to treat disease. The corporate strategy is simple – spend the next two years conducting “proof of concept” studies in melanoma patients, run animal trials in parallel targeting angiogenesis to confirm it as a platform technology, and then sell off the technology to the highest bidder. To use a baseball analogy, Scancell is heading to the plate and swinging for the fences. With a differentiated technology and a focused plan, we think this Company has what it takes to circle the bases. Read More \| Previous Reports


	SIGN UP NOW FOR OBJECTIVE'S STOCK RESEARCH - IT'S FREE! Objective, Independent, Experienced. Research you can trust!

	Yes! Subscribe me for the latest stock research from Objective.


	Email address

	My Password

	My information:
	First Name
	Family Name
	Title:

	Job title:
	Job function:
	Industry:
	I am a:
	To receive occasional printed reports complete your mailing address:
	Company Name (if any)
	Address


	City
	Postcode/Zip
	Country


	Please Read Objective's Terms of Use.

Objective Capital's Contact Information
Partnership, sales and product inquiries: marketing@objectivecapital.co.uk
Media services and conference requests: PR@objectivecapital.co.uk
Subscription and customer service issues: service@objectivecapital.co.uk
Comments or opinions on our analysis: analysis@objectivecapital.co.uk

11-12 Tokenhouse Yard, London EC2R 7AS, United Kingdom
ph +44-(0)870-080 2965 fax +44-(0)870-116 0839